Compare Gilead Sciences, Inc. (GILD) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kinder Morgan Inc — how do they compare? Gilead Sciences, Inc. trades at $135.12 (market cap $163.51B), while Kinder Morgan Inc trades at $32.66 (market cap $71.64B). The key difference: Gilead Sciences, Inc. is far larger — about 2.3× Kinder Morgan Inc's market cap, and Kinder Morgan Inc pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| GILD | KMI | |
|---|---|---|
Market Cap | $163.51B | $71.64B |
Sector | Health | Energy |
52-Week High | $155.80 | $34.31 |
52-Week Low | $108.22 | $25.84 |
Enterprise Value | $178.05B | $103.51B |
Dividend Yield | 2.49% | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Kinder Morgan (KMI) trades at $32.55, showing minimal daily movement with a slight 0.03% gain. The stock exhibits a bearish technical signal from moving averages, while fundamentals highlight strong profitability with an 18.92% net income margin and consistent earnings beats in recent quarters. Recent news emphasizes its stable cash flows from fee-based midstream contracts and growth driven by LNG and power demand, supported by a $10.1 billion project backlog.
KMI offers a balanced outlook with stable dividend income and growth potential from natural gas infrastructure investments, but faces risks from high debt levels and commodity price volatility. Analyst sentiment is mixed with a near-even split between Buy and Hold ratings, reflecting cautious optimism amid macroeconomic uncertainties. The stock's valuation at a P/E of 21.61 appears reasonable given its cash flow stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
